Blood-derived autografts collected during granulocyte colony-stimulating factor-enhanced recovery are enriched with early Thy-1+hematopoietic progenitor cells
It was the objective of the study to characterize CD34+ hematopoietic progenitor cells from peripheral blood (PB) and bone marrow (BM) in a group of 24 cancer patients. After cytotoxic chemotherapy, R-metHu granulocyte colony-stimulating factor (R-metHuG-CSF; filgrastim, 300 μ g daily, subcutaneousl...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
1 April 1995
|
| In: |
Blood
Year: 1995, Volume: 85, Issue: 7, Pages: 1936-1943 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood.V85.7.1936.bloodjournal8571936 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.V85.7.1936.bloodjournal8571936 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0006497120797727 
|
| Author Notes: | Rainer Haas, Robert Möhle, Margit Pförsich, Stefan Fruehauf, Barbara Witt, Hartmut Goldschmidt, Werner Hunstein |
| Summary: | It was the objective of the study to characterize CD34+ hematopoietic progenitor cells from peripheral blood (PB) and bone marrow (BM) in a group of 24 cancer patients. After cytotoxic chemotherapy, R-metHu granulocyte colony-stimulating factor (R-metHuG-CSF; filgrastim, 300 μ g daily, subcutaneously) was given to shorten the time of neutropenia as well as to increase the rebound of peripheral blood progenitor cells (PBPC) for harvesting. The proportion of CD34+ cells in the leukapheresis products (LPs) was 1.4-fold greater than in BM samples that were obtained at the same day (LP: median, 1.4% vBM: median, 1.0%, P ≪ .01). Two- and three- color immunofluorescence showed that blood-derived CD34+ cells comprised a greater proportion of a particular early progenitor cell than CD34+ cells of bone marrow. Blood-derived progenitor cells tended to have a higher mean fluorescence intensity of CD34 and expressed significantly lower levels of HLA-DR (mean fluorescence intensity of HLA- DR: 442.6 B1 44.9 [LP] v 661.5 B1 64.6 [BM], mean B1 SEM, P ≪ .01). Furthermore, the blood-derived CD34+ cells comprised a 1.7-fold greater proportion of Thy-1+ cells (LP: median, 24.4% v BM: median, 14.4%, P ≪ .001) and expressed significantly less c-kit (LP: median, 20.5% v BM: median, 31.0%, P ≪ .01). Three-color analysis showed that high levels of Thy-1 expression were restricted to CD34+/HLA-DRdim or CD34+/HLA-DR− cells confirming the early developmental stage of this progenitor cell subset. The proportion of CD34+/CD45RAbright cells representing late colony-forming unit granulocyte-macrophage (CFU-GM) was smaller in LPs compared with BM ( P ≪ .05). For an examination of BM CD34+ cells before the mobilization chemotherapy, samples of 16 patients were available. The mean proportion of c-kit expressing CD34+ ceils in the bone marrow during G-CSF- stimulated reconstitution decreased 1.8-fold compared with baseline values. There was no difference in the proportion of BM-derived CD34+/Thy-1+ cells and CD34+/CD45RA+ cells between steady-state hematopoiesis and G-CSF-supported recovery. Our data suggest that during G-CSF-enhanced recovery, CD34+ cells in the PB are enriched with more primitive progenitor cells to evenly replenish the BM after the chemotherapy-related cytotoxic damage. |
|---|---|
| Item Description: | Elektronische Reproduktion der Druck-Ausgabe 21. Dezember 2020 Im Titel ist "+" hochgestellt Gesehen am 19.05.2025 |
| Physical Description: | Online Resource |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood.V85.7.1936.bloodjournal8571936 |